How is IGA-AD graded?

IGA-AD: 0=clear (no signs), 1=almost clear (barely perceptible erythema, barely perceptible papulation/induration), 2=mild, 3=moderate (moderate erythema, obvious papulation, moist lesions, excoriation), 4=severe (intense erythema, marked papulation, oozing, crusting).

What IGA response is used in AD biologic trials?

IGA 0/1 with >=2 point improvement from baseline at week 16 is the co-primary endpoint (along with EASI-75) in most dupilumab, tralokinumab, and JAK inhibitor trials for moderate-to-severe AD.

Which JAK inhibitors are approved for AD?

Upadacitinib (JAK1, FDA 12+), abrocitinib (JAK1, FDA 12+), and baricitinib (JAK1/2, EMA/EU) are approved for moderate-to-severe AD. Upadacitinib 30mg achieves IGA 0/1 in ~48% at week 16.

IGA Atopic Dermatitis 0-4

Assess overall atopic dermatitis severity using IGA 0-4 scale. IGA 0 (clear) or 1 (almost clear) with >=2 grade improvement from baseline is the standard biologic trial co-primary endpoint.

Use the full interactive calculator below, or

Related Calculators

EASI Score

Hyper-niche Medical

IGA Atopic Dermatitis 0-4

Related Calculators

Frequently Asked Questions

How is IGA-AD graded?

What IGA response is used in AD biologic trials?

Which JAK inhibitors are approved for AD?